Silence Therapeutics (SLN)
NASDAQ:SLN
Want to see SLN full AI Analyst Report?
Top Page
Silence Therapeutics
(NASDAQ:SLN)
Select Model
Select Model
Rating:48Neutral
Price Target:
$6.00
▼(-20.32% Downside)
Action:Reiterated
Date:05/09/26
The score is held down primarily by weak financial performance (large losses and ongoing cash burn), with only partial offsets from low balance-sheet leverage and a mixed-to-improving medium-term technical backdrop. Valuation is constrained by negative earnings, while recent corporate updates are mixed (pipeline progress but a partner stepping away and a widening net loss).
Positive Factors
Balance Sheet Strength
Minimal financial leverage is a durable strength for a development-stage biotech: it reduces liquidity stress from interest obligations, preserves flexibility to fund R&D or partner deals, and lowers near-term default risk, extending runway compared with highly leveraged peers.
Negative Factors
Persistent Cash Burn
Continued negative operating and free cash flow is a durable pressure: it forces recurrent capital raises or partner financing, diluting shareholders and creating execution risk if funding terms worsen, while limiting the firm's ability to self-fund multiple late-stage programs simultaneously.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance Sheet Strength
Minimal financial leverage is a durable strength for a development-stage biotech: it reduces liquidity stress from interest obligations, preserves flexibility to fund R&D or partner deals, and lowers near-term default risk, extending runway compared with highly leveraged peers.
Read all positive factors
Silence Therapeutics (SLN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$292.85M
Dividend YieldN/A
Average Volume (3M)101.05K
Price to Earnings (P/E)―
Beta (1Y)1.40
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees116
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-3.66
Shares Outstanding47,234,610
10 Day Avg. Volume169,902
30 Day Avg. Volume101,050
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)4.61
Price to Sales (P/S)513.72
P/FCF Ratio-4.61
Enterprise Value/Market Cap0.98
Enterprise Value/Revenue342.76
Enterprise Value/Gross Profit512.64
Enterprise Value/Ebitda-4.07
Forecast
1Y Price Target
$27.59Price Target Upside266.40% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.54
Revenue Forecast (FY)$4.16M
Silence Therapeutics Business Overview & Revenue Model
Company Description
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi...
How the Company Makes Money
Silence Therapeutics primarily makes money through (1) collaboration and licensing arrangements with larger pharmaceutical/biotechnology companies and (2) funding related to its partnered R&D activities, with (3) potential future revenue from comm...
Silence Therapeutics Earnings Call Summary
Earnings Call Date:Feb 27, 2025
(Q4-2024)
| % Change Since: |
Next Earnings Date:Aug 06, 2026
Earnings Call Sentiment Neutral
The earnings call highlighted positive clinical trial results for zerlasiran and divesiran, revenue growth, and an extended cash runway. However, the termination of the Hansoh Pharma collaboration and the delay of the zerlasiran Phase 3 study due to the need for a partner were significant challenges mentioned.Positive Updates
Positive Results for Zerlasiran Phase 2 Study
The ALPACAR-360 Phase 2 study of zerlasiran in ASCVD patients with high Lp(a) delivered positive results, showing Lp(a) reductions exceeded 90% and were durable. The study was featured in a late-breaker at AHA and published in JAMA.
Negative Updates
Hansoh Pharma Collaboration Termination
Hansoh Pharma opted not to pursue further development under the collaboration, resulting in the company regaining rights to three undisclosed preclinical liver targets.
Read all updates
Q4-2024 Updates
Positive
Negative
Positive Results for Zerlasiran Phase 2 Study
The ALPACAR-360 Phase 2 study of zerlasiran in ASCVD patients with high Lp(a) delivered positive results, showing Lp(a) reductions exceeded 90% and were durable. The study was featured in a late-breaker at AHA and published in JAMA.
Read all positive updates
Company Guidance
During the call, Silence Therapeutics provided guidance on several key metrics for their future operations. The company reported $43.3 million in revenues for 2024, an increase from $31.6 million in 2023, largely due to collaboration arrangements. They ended 2024 with $147.3 million in cash, cash equivalents, and short-term investments. Silence announced they would only initiate the Phase 3 outcomes study for zerlasiran, their siRNA for high Lp(a), once a partner is secured, which extends their cash runway into 2027. Additionally, they are prioritizing investment in programs targeting rare conditions, like divesiran for polycythemia vera (PV), which has received orphan drug designation in both the EU and US. The company also plans to commence a Phase 1 study of SLN548 targeting complement factor B in the second half of 2025. Silence transitioned to a U.S. domestic issuer status, moving from IFRS to U.S. GAAP, which resulted in a net loss decrease to $45.3 million in 2024 from $54.2 million in 2023.Silence Therapeutics Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
64
Positive
Cash Flow
34
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 838.29K | 559.00K | 43.26M | 25.38M | 17.65M | 12.41M |
| Gross Profit | 560.49K | 344.00K | 31.45M | 15.06M | 6.68M | 4.96M |
| EBITDA | -70.55M | -89.20M | -48.99M | -49.78M | -49.27M | -45.42M |
| Net Income | -75.01M | -88.61M | -45.31M | -43.27M | -41.03M | -39.41M |
Balance Sheet | ||||||
| Total Assets | 115.12M | 131.44M | 202.63M | 119.45M | 107.50M | 96.19M |
| Cash, Cash Equivalents and Short-Term Investments | 70.08M | 85.11M | 147.33M | 68.79M | 71.14M | 73.54M |
| Total Debt | 136.00K | 160.00K | 117.00K | 346.00K | 446.00K | 137.00K |
| Total Liabilities | 65.72M | 69.14M | 68.61M | 97.45M | 85.43M | 87.67M |
| Stockholders Equity | 49.40M | 62.30M | 134.02M | 21.99M | 22.07M | 8.53M |
Cash Flow | ||||||
| Free Cash Flow | -65.67M | -62.33M | -67.85M | -39.40M | -57.59M | 7.39M |
| Operating Cash Flow | -65.56M | -62.27M | -67.64M | -39.35M | -57.04M | 9.19M |
| Investing Cash Flow | 6.39M | -47.99M | -21.97M | 16.43M | -20.50M | 11.71M |
| Financing Cash Flow | 986.00 | 15.00K | 142.09M | 25.16M | 52.58M | 41.45M |
Silence Therapeutics Technical Analysis
Negative
7.53
Price Trends
6.58
Negative
6.00
Positive
5.97
Positive
Market Momentum
-0.16
Positive
43.74
Neutral
34.42
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SLN, the sentiment is Negative. The current price of 7.53 is above the 20-day moving average (MA) of 6.89, above the 50-day MA of 6.58, and above the 200-day MA of 5.97, indicating a neutral trend. The MACD of -0.16 indicates Positive momentum. The RSI at 43.74 is Neutral, neither overbought nor oversold. The STOCH value of 34.42 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SLN.
Silence Therapeutics Risk Analysis
Silence Therapeutics disclosed 61 risk factors in its most recent earnings report. Silence Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Silence Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | $310.05M | -3.71 | 41.40% | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $233.12M | -1.70 | -2781.56% | ― | 289.94% | 16.60% | |
50 Neutral | $776.48M | ― | 87.31% | ― | ― | -1004.74% | |
48 Neutral | $292.85M | -4.17 | -107.23% | ― | ― | ― | |
41 Neutral | $164.64M | -9.09 | 21.05% | ― | ― | 43.38% |
* Healthcare Sector Average
SLN
Silence Therapeutics
6.20
1.14
22.53%
GALT
Galectin Therapeutics
2.50
1.22
95.31%
ABEO
Abeona Therapeutics
5.44
-0.98
-15.26%
HUMA
Humacyte
1.05
-1.48
-58.50%
VOR
Vor Biopharma
14.33
10.86
312.97%
Silence Therapeutics Corporate Events
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
Silence Therapeutics Establishes New At-The-Market Program
Neutral
May 18, 2026
On May 18, 2026, Silence Therapeutics entered a new Open Market Sale Agreement with Jefferies LLC, allowing the biotech group to sell American Depositary Shares from time to time in at-the-market offerings, replacing a prior 2021 agreement that wa...
Business Operations and StrategyExecutive/Board ChangesFinancial Disclosures
Silence Therapeutics Updates Pipeline, Reports 2025 Financial Results
Negative
Mar 5, 2026
On 5 March 2026, Silence Therapeutics reported fourth-quarter and full-year 2025 results, highlighting clinical progress across its siRNA pipeline and an updated corporate presentation. The company said enrollment in its Phase 2 SANRECO trial of d...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.